This study aims to find new ways to diagnose celiac disease without needing a biopsy. Celiac disease (CD) is when the body reacts badly to gluten, a protein in wheat. To diagnose CD, doctors often use a test called the IgA anti-tissue transglutaminase (tTG-IgA) antibody test. This study will check if a high level of this antibody (10 times the normal limit) can confirm CD without a biopsy.
The study will involve both children and adults who are newly diagnosed with CD in 2023 and 2024. Participants will need to give blood samples to test for tTG-IgA levels. The tests will be done in different hospitals and then checked at a main hospital, Hospital Universitario La Paz.
- Study is for newly diagnosed patients in 2023-2024.
- Participants need to give blood samples for testing.
- No biopsy needed if antibody levels are very high.
How understandable was the trial content above?
Hard to understand
Easy to understand